NCT01989455View on ClinicalTrials.gov

A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Healthy Volunteers
Interventions
DRUG

Deferiprone

"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"

DRUG

Placebo

Placebo: normal saline solution.

Trial Locations (1)

H3P3P1

Algorithme Pharma Inc., Mount Royal

Sponsors

Lead Sponsor

ApoPharma
All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT01989455 - A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers | Biotech Hunter | Biotech Hunter